(Q28265862)

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Human cerebrovascular contractile receptors are upregulated via a B-Raf/MEK/ERK-sensitive signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Antitumor activity of sorafenib in FLT3-driven leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Overview of anti-angiogenic agents in development for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Drug discovery: inhibitors that activate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

BRAF signaling and targeted therapies in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Guilty as charged: B-RAF is a human oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

B-RAF is a therapeutic target in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Selective Raf inhibition in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Rational design of inhibitors that bind to inactive kinase conformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Design and discovery of small molecules targeting raf-1 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Discovery of a novel Raf kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Targeting the RAF-MEK-ERK pathway in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Clinical overview of sorafenib in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

A phase II trial of sorafenib in metastatic melanoma with tissue correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Mitogen-activated protein kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

BRAF is a therapeutic target in aggressive thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Understanding Ras: 'it ain't over 'til it's over'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

The identification of potent and selective imidazole-based inhibitors of B-Raf kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

BRAF as therapeutic target in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5

The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-0403-5